GPR160與前列腺癌相關(guān)性首次得以揭示
發(fā)布時間：2019-06-06 12:23
【摘要】：正中科院上海藥物研究所國家新藥篩選中心王明偉課題組與丁健課題組合作,首次揭示了GPR160與前列腺癌的相關(guān)性,為靶向GPR160的抗前列腺癌藥物發(fā)現(xiàn)奠定了基礎(chǔ)。相關(guān)研究成果已在線發(fā)表于《腫瘤靶點》。據(jù)悉,G蛋白偶聯(lián)受體(GPCR)是目前最為成功的藥物靶標家族,其在腫瘤發(fā)生和發(fā)展過程中的作用日益受到關(guān)注。
[Abstract]:Wang Mingwei, National Drug screening Center of Shanghai Institute of Medicine, Chinese Academy of Sciences, worked with Ding Jian to reveal the correlation between GPR160 and prostate cancer for the first time, which laid a foundation for the discovery of anti-prostate cancer drugs targeting GPR160. The related research results have been published online in tumor Target. It is reported that G protein-coupled receptor (GPCR) is the most successful drug target family at present, and its role in tumorigenesis and development has been paid more and more attention.
【分類號】：R737.25
，
本文編號：2494362
[Abstract]:Wang Mingwei, National Drug screening Center of Shanghai Institute of Medicine, Chinese Academy of Sciences, worked with Ding Jian to reveal the correlation between GPR160 and prostate cancer for the first time, which laid a foundation for the discovery of anti-prostate cancer drugs targeting GPR160. The related research results have been published online in tumor Target. It is reported that G protein-coupled receptor (GPCR) is the most successful drug target family at present, and its role in tumorigenesis and development has been paid more and more attention.
【分類號】：R737.25
，
本文編號：2494362
本文鏈接：http://sikaile.net/yixuelunwen/mjlw/2494362.html
最近更新
教材專著
